ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2077

A Curriculum of Online Education Significantly Improved Rheumatologists’ Knowledge, Competence and Confidence in Managing Patients with Spondyloarthritis
Abstract Number: 1398

A Deep Learning Algorithm for MRI Spinal Inflammation in Axial Spondyloarthritis
Abstract Number: 1876

A Deep Learning System for Automated Assessing Microcirculation Abnormalities in Nailfold Capillaroscopy Images of Systemic Sclerosis
Abstract Number: 0665

A Descriptive Study of Disease Characterisics of SSc Patients with the U2RNP Autoantibody
Abstract Number: 1124

A Double-blind, Placebo-parallel Controlled Phase III Clinical Study of the Efficacy and Safety of Hemay005 Tablets in Patients with Moderate to Severe Chronic Plaque Psoriasis in China
Abstract Number: 0738

A Genome-wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome
Abstract Number: 0632

A Longitudinal Analysis of Mouth Opening in 1101 Systemic Sclerosis Patients from the French National Cohort Study
Abstract Number: 1846

A Longitudinal Study: The Benefits of Non-Pharmacological Approaches to Improve Self-Reported Pain, Stiffness, and Fatigue in Individuals with Musculoskeletal Disorders
Abstract Number: 2356

A Macrophage-Specific Mechanism for Mycophenolate Mofetil in the Treatment of Systemic Sclerosis
Abstract Number: 2062

A Mental Health Workshop for Pediatric Rheumatology Fellows
Abstract Number: 0274

A Mix-and-match COVID-19 Vaccination Strategy in Patients with Rheumatic Diseases on Rituximab
Abstract Number: 0771

A Modified Idiopathic Pulmonary Fibrosis-Derived Composite Biomarker Score Is Associated with Interstitial Lung Disease Among U.S. Veterans with Rheumatoid Arthritis
Abstract Number: 0430

A Multicenter, Real-world Clinical Data Study of the Use of JAK Kinase Inhibitors in a Large Cohort of Patients with Rheumatoid Arthritis
Abstract Number: 1003

A Multidisciplinary Obstetric-Medicine/Rheumatology Specialty Clinic in the United States: A Five Year Analysis
Abstract Number: 2067

A New Tool Assessing Trainees’ Interventional Musculoskeletal Ultrasound Skills

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].